Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Sinopharm Group Co ( (HK:1099) ) is now available.
Sinopharm Group Co. Ltd. announced the current composition of its board of directors and the roles and functions of each director, distinguishing between non-executive, executive, and independent non-executive directors. The company also disclosed the membership structure of its five board committees—Audit, Remuneration, Nomination, Strategy and Investment, and Legal and Compliance and Environmental, Social and Governance—clarifying the chairpersons and members of each, which enhances governance transparency for shareholders and other stakeholders.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading Chinese state-backed pharmaceutical and healthcare distributor, active in the research, manufacturing, and distribution of medicines and medical products, and carries on business in Hong Kong through its listing on the Stock Exchange of Hong Kong. The company plays a key role in the mainland China pharmaceutical supply chain and related healthcare services, serving hospitals, pharmacies, and other medical institutions.
Average Trading Volume: 4,792,532
Technical Sentiment Signal: Buy
Current Market Cap: HK$61.23B
See more insights into 1099 stock on TipRanks’ Stock Analysis page.